Oncotalks | Powered by Novartis

ESMO

Interviews recorded at the European Socitey for Medical Oncology congress

ESMO 2019 Oreste Gentilini, MD, PhD; Treating young patients with BRCA-mutated early breast cancers

ESMO 2019 Oreste Gentilini, MD, PhD; Treating young patients with BRCA-mutated early breast cancers

Oreste Gentilini, MD, PhD from the European Institute of Oncology Milano, Milan, Italy is commenting on a session he chaired: Multidisciplinary session: Treating young patients with BRCA-mutated early breast cancers

ESMO , Lithuania , Albania

00:04:53

ESMO 2019 Piotr Rutowski, MD, PhD; Multidisciplinary session: Perioperative therapy in melanoma

ESMO 2019 Piotr Rutowski, MD, PhD; Multidisciplinary session: Perioperative therapy in melanoma

Piotr Rutowski, MD, PhD from the Maria Sklodowska-Curie Memorial Cancer Center and Institute, Warsaw, Poland is commenting on the session he chaired: Multidisciplinary session: Perioperative therapy in melanoma

ESMO , Hungary , Lithuania , Albania

00:06:30

ESMO 2019 Ana Arance, MD, PhD; Melanoma and other skin tumours

ESMO 2019 Ana Arance, MD, PhD; Melanoma and other skin tumours

Ana Arance, MD, PhD from the Hospital Clínic Barcelona, Barcelona, Spain is commenting on a session she chaired: Poster discussion: Melanoma and other skin tumours

ESMO , Hungary , Lithuania , Albania

00:04:15

ESMO 2019 Bogumiła Czartoryska-Arłukowicz, MD;

ESMO 2019 Bogumiła Czartoryska-Arłukowicz, MD;

Bogumiła Czartoryska-Arłukowicz, MD from the Białostockie Centrum Onkologii, Białystok, Poland

ESMO , Lithuania

00:03:10

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania

00:03:29

ESMO 2019- Highlights on breast cancer presented at ESMO 2019

ESMO 2019- Highlights on breast cancer presented at ESMO 2019

Conleth Murphy, MD, PhD and Ivan Bilic, MD, PhD sharing their personal highlights on breast cancer presented at ESMO 2019 in Barcelona

ESMO , Latvia , Lithuania , Estonia , Albania

00:02:21

ESMO 2019 prof. Sherko Kümmel, MD; LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 prof. Sherko Kümmel, MD; LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial

prof. Sherko Kümmel, MD from the Kliniken Essen-Mitte, Essen, Germany is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Hungary , Lithuania , Albania , Slovenia

00:02:45

ESMO 2019 Prof. Dirk de Ruysscher, MD; ESMO-ESTRO Collaborative session: RTCT in stage III NSCLC: Prevention and management of toxicity including the use of immunotherapy

ESMO 2019 Prof. Dirk de Ruysscher, MD; ESMO-ESTRO Collaborative session: RTCT in stage III NSCLC: Prevention and management of toxicity including the use of immunotherapy

Prof. Dirk de Ruysscher, MD from the Maastricht UMC+, Maastricht, The Netherlands is commenting on a session he chaired: ESMO-ESTRO Collaborative session: RTCT in stage III NSCLC: Prevention and management of toxicity including the use of immunotherapy

ESMO , Lithuania , Albania

00:03:03

ESMO 2019 Highlights on melanoma presented at ESMO 2019

ESMO 2019 Highlights on melanoma presented at ESMO 2019

Philippe Saiag, MD, PhD and Prof. Jean Jacques Grob, MD are sharing their personal hightlights on melanoma from ESMO 2019

ESMO , Latvia , Lithuania , Estonia , Hungary , Albania

00:02:10

ESMO 2019 Lizza Hendriks, MD, PhD; Multidisciplinary session: Oligorecurrent and oligoprogressive NSCLC

ESMO 2019 Lizza Hendriks, MD, PhD; Multidisciplinary session: Oligorecurrent and oligoprogressive NSCLC

Lizza Hendriks, MD, PhD from the MUMC+, Maastricht, The Netherlands is commenting on the session she chaired: Multidisciplinary session: Oligorecurrent and oligoprogressive NSCLC

ESMO , Lithuania , Albania

00:03:55

ESMO 2019 Aleix Prat, MD, PhD; Optimal adjuvant and neo-adjuvant therapy in HER-2+ patients

ESMO 2019 Aleix Prat, MD, PhD; Optimal adjuvant and neo-adjuvant therapy in HER-2+ patients

Aleix Prat, MD, PhD from the Hospital Clínic of Barcelona, Barcelona, Spain is commenting on the session he chaired Educational session: Optimal adjuvant and neo-adjuvant therapy in HER-2+ patients

ESMO , Lithuania , Albania

00:04:44

ESMO 2019 Prof. Mario Campone, MD; Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial

ESMO 2019 Prof. Mario Campone, MD; Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial

Prof. Mario Campone, MD from the Institut de Canceérologie de L’Ouest, Saint Herblain, France is commenting on the abstract Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial

ESMO , Kisqali Channel , Lithuania , Albania

00:02:11

1
2
3
4